181 related articles for article (PubMed ID: 29895383)
1. Extending the use of stiripentol to SLC13A5-related epileptic encephalopathy.
Alhakeem A; Alshibani F; Tabarki B
Brain Dev; 2018 Oct; 40(9):827-829. PubMed ID: 29895383
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome.
Yıldız EP; Ozkan MU; Uzunhan TA; Bektaş G; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
J Child Neurol; 2019 Jan; 34(1):33-37. PubMed ID: 30362398
[TBL] [Abstract][Full Text] [Related]
3. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
Trivisano M; Specchio N; Vigevano F
Eur J Paediatr Neurol; 2015 Mar; 19(2):248-50. PubMed ID: 25510386
[TBL] [Abstract][Full Text] [Related]
4. Stiripentol for the treatment of seizures in Dravet syndrome.
Eschbach K; Knupp KG
Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
[TBL] [Abstract][Full Text] [Related]
5. Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene.
Matricardi S; De Liso P; Freri E; Costa P; Castellotti B; Magri S; Gellera C; Granata T; Musante L; Lesca G; Oertel J; Craiu D; Hammer TB; Møller RS; Barisic N; Abou Jamra R; Polster T; Vigevano F; Marini C
Epilepsia; 2020 Nov; 61(11):2474-2485. PubMed ID: 33063863
[TBL] [Abstract][Full Text] [Related]
6. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
[TBL] [Abstract][Full Text] [Related]
7. Combination of ketogenic diet and stiripentol for super-refractory status epilepticus: A case report.
Uchida Y; Kato D; Toyoda T; Oomura M; Ueki Y; Ohkita K; Matsukawa N
J Neurol Sci; 2017 Feb; 373():35-37. PubMed ID: 28131220
[No Abstract] [Full Text] [Related]
8. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
Buck ML; Goodkin HP
Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540
[No Abstract] [Full Text] [Related]
9. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.
Myers KA; Lightfoot P; Patil SG; Cross JH; Scheffer IE
Dev Med Child Neurol; 2018 Jun; 60(6):574-578. PubMed ID: 29473155
[TBL] [Abstract][Full Text] [Related]
10. Stiripentol in the Management of Epilepsy.
Nickels KC; Wirrell EC
CNS Drugs; 2017 May; 31(5):405-416. PubMed ID: 28434133
[TBL] [Abstract][Full Text] [Related]
11. Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Kopel J; Grooms A; Ganapathy V; Clothier J
Psychiatr Genet; 2021 Feb; 31(1):32-35. PubMed ID: 33290383
[TBL] [Abstract][Full Text] [Related]
12. [Dravet syndrome is a rare genetic epileptic disorder that can be mistaken for fever cramps].
Johannesen KM; Hansen MB
Ugeskr Laeger; 2014 Mar; 176(14):. PubMed ID: 25350058
[TBL] [Abstract][Full Text] [Related]
13. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam.
Strzelczyk A; Schubert-Bast S; Reese JP; Rosenow F; Stephani U; Boor R
Epilepsy Behav; 2014 May; 34():86-91. PubMed ID: 24727467
[TBL] [Abstract][Full Text] [Related]
15. Stiripentol for the treatment of super-refractory status epilepticus.
Strzelczyk A; Kortland LM; Knake S; Rosenow F
Acta Neurol Scand; 2015 Dec; 132(6):435-9. PubMed ID: 25809474
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of add-on stiripentol in real-world clinical practice: An observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies.
Gil-Nagel A; Aledo-Serrano A; Beltrán-Corbellini Á; Martínez-Vicente L; Jimenez-Huete A; Toledano-Delgado R; Gacía-Morales I; Valls-Carbó A
Epilepsia Open; 2024 Feb; 9(1):164-175. PubMed ID: 37867433
[TBL] [Abstract][Full Text] [Related]
17. Stiripentol for the treatment of seizures associated with Dravet syndrome.
Chiron C
Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
[TBL] [Abstract][Full Text] [Related]
18. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia.
Hardies K; de Kovel CG; Weckhuysen S; Asselbergh B; Geuens T; Deconinck T; Azmi A; May P; Brilstra E; Becker F; Barisic N; Craiu D; Braun KP; Lal D; Thiele H; Schubert J; Weber Y; van 't Slot R; Nürnberg P; Balling R; Timmerman V; Lerche H; Maudsley S; Helbig I; Suls A; Koeleman BP; De Jonghe P;
Brain; 2015 Nov; 138(Pt 11):3238-50. PubMed ID: 26384929
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
[TBL] [Abstract][Full Text] [Related]
20. Novel Homozygous Variants of SLC13A5 Expand the Functional Heterogeneity of a Homogeneous Syndrome of Early Infantile Epileptic Encephalopathy.
Alsemari A; Guzmán-Vega FJ; Meyer BF; Arold ST
Pediatr Neurol; 2024 Feb; 151():68-72. PubMed ID: 38113697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
